相关实验视频
Updated: Jun 24, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.3K
B7-H3和ICAM-1是甲状腺癌的潜在治疗点
Pengtao Song1,2, Yongcan Xu3,4, Guochao Ye5,6
1Department of Pathology, Fifth School of Clinical Medicine of Zhejiang, Huzhou Central Hospital, Chinese Medical University, Huzhou, People's Republic of China.
Diagnostic pathology
|June 10, 2024
概括
这项研究研究了甲状腺癌中B7-H3和ICAM-1的表达,发现它们在乳头和形类型上升调节,这表明免疫疗法组合治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 差异化甲状腺癌通常有良好的预后,但攻击性的亚型,如形甲状腺癌和晚期乳头甲状腺癌是致命的.
- 需要新的治疗方法,包括针对免疫检查点 (ICP) 的免疫疗法,用于晚期甲状腺癌.
- B7-H3 (B7同源3蛋白) 和ICAM-1 (细胞间粘附分子1) 是越来越多地被认为是潜在的治疗点的ICP.
研究的目的:
- 在各种类型的甲状腺癌中探索B7-H3和ICAM-1的表达水平.
- 调查B7-H3和ICAM-1表达和临床参数之间的相关性.
- 评估针对B7-H3和ICAM-1在晚期甲状腺癌中进行组合免疫治疗的潜力.
主要方法:
- 在TCGA甲状腺癌队列中分析B7-H3和ICAM-1mRNA表达.
- 从临床队列中评估B7-H3和ICAM-1蛋白表达在乳头甲状腺癌 (PTC) 和形甲状腺癌 (ATC) 中.
- 统计分析以确定B7-H3和ICAM-1表达与临床数据及其相互关系的相关性.
主要成果:
- 在TCGA队列中,B7-H3和ICAM-1mRNA都在甲状腺癌中高度表达.
- 较低的B7-H3和ICAM-1mRNA表达在患有第二阶段,年龄61-80岁,毛囊性甲状腺癌的毛囊型变异和N0.0的患者中观察到.
- 临床队列中的PTC和ATC经常表现出中度至强度的B7-H3和ICAM-1蛋白表达.
- 在TCGA数据库和临床队列中,B7-H3和ICAM-1染色得分之间发现了显著的相关性.
结论:
- B7-H3和ICAM-1在侵袭性甲状腺癌中经常过度表达,包括PTC和ATC.
- B7-H3和ICAM-1的表达水平与某些临床参数相关.
- B7-H3和ICAM-1之间的显著关联表明它们有可能成为晚期甲状腺癌组合免疫治疗的点.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Immunoglobulin-like Cell Adhesion Molecules
3.2K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.2K
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Synthesis and Regulation of Thyroid Hormones
4.5K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.5K

